Research programme: Rel protein inhibitors - BioLineRx/Hebrew University of Jerusalem

Drug Profile

Research programme: Rel protein inhibitors - BioLineRx/Hebrew University of Jerusalem

Alternative Names: EDP 25

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer BioLineRx; Hebrew University of Jerusalem
  • Class
  • Mechanism of Action Bacterial protein inhibitors; Proto-oncogene protein c-rel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Bacterial-infections in Israel
  • 27 Sep 2013 Early research is ongoing in Israel
  • 28 Sep 2011 Early research in Bacterial infections in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top